Vaxcyte, Inc. PCVX

US Biotechnology

$67.53 ▲ +5.70% (+$3.64)

Open $64.75

Prev Close $63.89

Day Range $63.93 – $67.62

52W Range $40.14 – $90.75

Market Cap $10.63B

Beta 1.26

EPS (TTM) $-7.64

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2020-06-12
Shares Out.	152,200,000
Website	vaxcyte.com/ ↗
Phone	13026587581
Employees	507
Revenue	$0
Gross Profit	$0
Net Income	-$284.3M
Free Cash Flow	-$921.1M
Total Assets	$3.14B
Total Liabilities	$380.2M
Equity	$2.76B

About Vaxcyte, Inc.

Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.

Vaxcyte, Inc. is a publicly traded company under the ticker symbol PCVX on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.